vs
Hillman Solutions Corp.（HLMN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Hillman Solutions Corp.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.8倍（$370.1M vs $207.3M），Hillman Solutions Corp.净利率更高（-1.3% vs -62.0%，领先60.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.0%），Hillman Solutions Corp.自由现金流更多（$-34.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.2%）
Hillman Solutions是一家美国企业，核心业务涵盖五金产品制造、分销以及面向消费者的定制加工服务，为市场提供多元化的五金相关解决方案，服务覆盖产业链多个环节。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HLMN vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $370.1M | $207.3M |
| 净利润 | $-4.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 1.9% | -54.7% |
| 净利率 | -1.3% | -62.0% |
| 营收同比 | 3.0% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $-0.02 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $370.1M | — | ||
| Q4 25 | $365.1M | $207.3M | ||
| Q3 25 | $424.9M | $159.9M | ||
| Q2 25 | $402.8M | $166.5M | ||
| Q1 25 | $359.3M | $139.3M | ||
| Q4 24 | $349.6M | $164.6M | ||
| Q3 24 | $393.3M | $139.5M | ||
| Q2 24 | $379.4M | $147.0M |
| Q1 26 | $-4.7M | — | ||
| Q4 25 | $1.6M | $-128.6M | ||
| Q3 25 | $23.2M | $-180.4M | ||
| Q2 25 | $15.8M | $-115.0M | ||
| Q1 25 | $-317.0K | $-151.1M | ||
| Q4 24 | $-1.2M | $-133.2M | ||
| Q3 24 | $7.4M | $-133.5M | ||
| Q2 24 | $12.5M | $-131.6M |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 4.6% | -54.7% | ||
| Q3 25 | 10.8% | -106.9% | ||
| Q2 25 | 9.0% | -64.8% | ||
| Q1 25 | 4.2% | -102.6% | ||
| Q4 24 | 4.0% | -74.3% | ||
| Q3 24 | 6.8% | -94.6% | ||
| Q2 24 | 8.3% | -79.1% |
| Q1 26 | -1.3% | — | ||
| Q4 25 | 0.4% | -62.0% | ||
| Q3 25 | 5.5% | -112.8% | ||
| Q2 25 | 3.9% | -69.0% | ||
| Q1 25 | -0.1% | -108.5% | ||
| Q4 24 | -0.3% | -80.9% | ||
| Q3 24 | 1.9% | -95.7% | ||
| Q2 24 | 3.3% | -89.5% |
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.00 | $-1.28 | ||
| Q3 25 | $0.12 | $-1.81 | ||
| Q2 25 | $0.08 | $-1.17 | ||
| Q1 25 | $0.00 | $-1.57 | ||
| Q4 24 | $-0.00 | $-1.34 | ||
| Q3 24 | $0.04 | $-1.40 | ||
| Q2 24 | $0.06 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.7M | $421.0M |
| 总债务越低越好 | $714.1M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.59× | — |
8季度趋势，按日历期对齐
| Q1 26 | $27.7M | — | ||
| Q4 25 | $27.3M | $421.0M | ||
| Q3 25 | $37.7M | $202.5M | ||
| Q2 25 | $34.2M | $176.3M | ||
| Q1 25 | $36.3M | $127.1M | ||
| Q4 24 | $44.5M | $174.0M | ||
| Q3 24 | $59.8M | $150.6M | ||
| Q2 24 | $54.0M | $480.7M |
| Q1 26 | $714.1M | — | ||
| Q4 25 | $668.3M | — | ||
| Q3 25 | $683.2M | — | ||
| Q2 25 | $683.1M | — | ||
| Q1 25 | $713.5M | — | ||
| Q4 24 | $691.7M | — | ||
| Q3 24 | $730.7M | — | ||
| Q2 24 | $732.1M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.2B | $144.2M | ||
| Q4 24 | $1.2B | $255.0M | ||
| Q3 24 | $1.2B | $346.8M | ||
| Q2 24 | $1.2B | $432.4M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.4B | $1.3B | ||
| Q1 25 | $2.3B | $1.3B | ||
| Q4 24 | $2.3B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.6B |
| Q1 26 | 0.59× | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.56× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-34.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | -9.3% | -48.6% |
| 资本支出强度资本支出/营收 | 4.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $22.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $30.9M | $-99.8M | ||
| Q3 25 | $26.2M | $-91.4M | ||
| Q2 25 | $48.7M | $-108.3M | ||
| Q1 25 | $-655.0K | $-166.5M | ||
| Q4 24 | $43.1M | $-79.3M | ||
| Q3 24 | $63.7M | $-67.0M | ||
| Q2 24 | $64.8M | $-77.0M |
| Q1 26 | $-34.3M | — | ||
| Q4 25 | $16.1M | $-100.8M | ||
| Q3 25 | $9.1M | $-92.7M | ||
| Q2 25 | $31.2M | $-110.7M | ||
| Q1 25 | $-21.3M | $-167.8M | ||
| Q4 24 | $22.1M | $-79.5M | ||
| Q3 24 | $39.6M | $-68.6M | ||
| Q2 24 | $42.5M | $-79.0M |
| Q1 26 | -9.3% | — | ||
| Q4 25 | 4.4% | -48.6% | ||
| Q3 25 | 2.1% | -58.0% | ||
| Q2 25 | 7.7% | -66.5% | ||
| Q1 25 | -5.9% | -120.5% | ||
| Q4 24 | 6.3% | -48.3% | ||
| Q3 24 | 10.1% | -49.2% | ||
| Q2 24 | 11.2% | -53.7% |
| Q1 26 | 4.0% | — | ||
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 4.0% | 0.8% | ||
| Q2 25 | 4.3% | 1.5% | ||
| Q1 25 | 5.7% | 1.0% | ||
| Q4 24 | 6.0% | 0.1% | ||
| Q3 24 | 6.1% | 1.2% | ||
| Q2 24 | 5.9% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 19.33× | — | ||
| Q3 25 | 1.13× | — | ||
| Q2 25 | 3.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.57× | — | ||
| Q2 24 | 5.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HLMN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
